Latest "UCOPIA Communications" News Stories

04:25 EST 13th December 2018 | BioPortfolio

Here are the most relevant search results for "UCOPIA Communications" found in our extensive news archives from over 250 global news sources.

More Information about UCOPIA Communications on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about UCOPIA Communications for you to read. Along with our medical data and news we also list UCOPIA Communications Clinical Trials, which are updated daily. BioPortfolio also has a large database of UCOPIA Communications Companies for you to search.

Showing "UCOPIA Communications" News Articles 1–25 of 1,300+

Wednesday 12th December 2018

11 new epilepsy genes discovered

Epilepsy researchers from around the world examined the DNA of more than 45,000 people and have discovered 11 genes associated with the disorder. Researchers led by University of Melbourne clinical neurologist Sam Berkovic compared the DNA of more than 15,000 people with epilepsy to the DNA of 30,000 control people without the disorder. The results, published in Nature Communications, tripled th...

MD Magazine® Expands Strategic Alliance Partnership Program with the University of New Mexico Health Sciences Center

The partners will collaborate to help improve health care in New Mexico MD Magazine®, a digital portal focused on providing physicians with the most valuable, up-to-date specialty and disease-specific resources to help them provide the best patient care, welcomes the University of New Mexico Health Sciences Center (UNM HSC) to its Strategic All...

Clark Health Communications to bring AI to the forefront with new deal

Partners up with Egg Digital

Clark Health Communications to bring AI at the forefront with new deal

Partners up with Egg Digital

Genprex to Launch Investors Website and Increase Emphasis on Investor Relations in 2019

Company Placing Priority on Investor Engagement with New Website, Email Updates Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, a

Vocera Improves Clinical Workflows at a North Carolina Hospital

Technology helps enhance surveillance monitoring and patient experience Vocera Communications, Inc. (NYSE:VCRA), a recognized leader in clinical communication and workflow solutions, today announced that Wake Forest Baptist Health deployed Vocera technology at a second hospital, Wake Forest Baptist Health Davie Medical Center, to improve clinical ...

Gibson’s Novel Anti-cancer Drug, LMP-400, Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing Sarcoma

Gibson Oncology, LLC (“Gibson”), a privately held clinical stage company developing a novel class of oncology drugs for treating adult and pediatric cancers resistant to traditional cancer drugs, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to LMP-400, Gibson’s novel small mole...

Development of world's first vertical Ga2O3 transistor through ion implantation doping

Researchers at the National Institute of Information and Communications Technology (NICT) and Tokyo University of Agriculture and Technology (TUAT) demonstrate a vertical Ga2O3 metal-oxide-semiconductor field-effect transistor (MOSFET) that adopts an all-ion-implanted process for both n-type and p-type doping, paving the way for new generations of low-cost and highly-manufacturable Ga2O3 power ele...

Full-Service Digital Agency Mostly Serious Launches Rebranded Website for Burrell Behavioral Health

Burrell Behavioral Health, a community mental health clinic serving more than 40,000 clients in Missouri, tapped the digital agency to lead its new brand identity design and website. SPRINGFIELD, Mo. (PRWEB) December 12, 2018 Mostly Serious, a full-service digital agency specializing in responsive web design and interactive marketing, recently launched a new website for Burrell Behavioral Health,...

Avacta appoints Dr Jose Saro as Chief Medical Officer

Dr Jose Saro joins Avacta from Roche to lead the Group’s Affimer® therapeutic development strategy and drive the in-house programmes into the clinic Cambridge, UK, 12 December 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that Dr Jose Saro has been appointed as Chief Medical Officer to lead the Group’s ...

Kantar Health Named One of "Best Companies to Work For® in Greater China" by Great Place to Work®

SHANGHAI, Dec. 12, 2018 /PRNewswire/ -- Kantar Health, a global leader in healthcare consulting, has been named one of the "Best Companies to Work For® in Greater China" by Great Place to Work®. This year, 36 companies made it to the list. More than 150 companies were surveyed for the 2018 list, which Great Place to Work produced after receiving employ...

CELLULES SOUCHES et SNC : L'échafaudage biodégradable qui facilite la greffe

C’est une nouvelle étape qui vient d’être franchie dans les nouvelles technologies de thérapie par cellules souches des maladies et des traumatismes du système nerveux central (SNC) avec cet échafaudage biodégradable, développé par une équipe de l’Université Rutgers (New Jersey) et présenté dans la revue Nature Communications. Ce nouveau nano-dispositif permet de réduire la lent...

Clark Health Communications forms alliance with Egg

London-based consultancy Clark Health Communications is partnering with digital solutions agency Egg in a collaboration that will see them offer their services to each other’s clients. The move could combine Clark Health Communications' medical co...

Tuesday 11th December 2018

British American Tobacco Launches 2018 Harm Reduction Focus Report

Report highlights British American Tobacco’s progress on its ambition to transform tobacco with a range of potentially reduced-risk products. SOURCE: ReportAlert DESCRIPTION:British American Tobacco’s strategy of transforming tobacco by seeking to provide consumers with satisfying, reduced-risk alternatives to smoking is the focus of its latest report, available now. This new report highlights...

Link between poverty and obesity is only about 30 years old, study shows

It's a fact: poverty and obesity are intimately connected. But this relationship is only about 30 years old, according to a new study coauthored by UT researchers and published in Palgrave Communications, an open-access, online journal.

MetrioPharm AG: MetrioPharm AG Closes Financing Round of CHF 20 Million

EQS Group-News: MetrioPharm AG / Key word(s): Financing/Capital Increase 11.12.2018 / 16:46 Zurich, December 11, 2018. MetrioPharm AG, a clinical stage pharmaceutical development company, announces that it has successfully completed the current financing round D. MetrioPharm CEO Dr. Wolfgang Brysch: "We are pleased to have completed the current financing round as planned in 2018. Altoget...

New Genes Linked to Epilepsy May Open Doors to Novel Therapies

An international team of researchers, including scientists at the Royal College of Surgeons in Ireland (RCSI), has discovered 11 new genes associated with epilepsy. The study (“Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies”), published in Nature Communications, greatly advances knowledge of the underlying biological causes of...

Blue Water Selected as Digital Agency Partner by Academy of Managed Care Pharmacy

Award-Winning DC Experience Agency, Blue Water, teams up with AMCP to revamp digital presence. Blue Water is thrilled to have been selected by the Academy of Managed Care Pharmacy (AMCP) to spearhead the consolidation and modernization of its digital properties to deliver a cohesive and enhanced experience for members and non-members alike. A...

Axis Communications Partners with Nemours Children’s Hospital to Deliver Unprecedented Pediatric Care

Axis cameras provide additional eyes for paramedics in the Tactical Logistics Center to help nurses, doctors and parents continuously monitor patient vitals, detect small visual changes in health and accelerate emergency response. Axis Communications, the market leader in network video, today announced that Nemours

Ordergroove Showcases Innovations in Relationship Commerce with Leading Retailers

Customer-centric experiences demonstrated at NRF 2019 Booth 4364 Ordergroove, the leader in Relationship Commerce, today announced the demonstration of frictionless, customer-centric shopping experiences with customers illy, bareMinerals, GNC and Tractor Supply in the Ordergroove booth at National Retail Federation (NRF) 2019: Retail’s Big Show, to b...

IONTAS Founder and Phage Display Pioneer Attends Nobel Prize Award Ceremony

Dr John McCafferty celebrates success of phage display technology with Nobel Prize in Chemistry Laureates IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced its Founder and Chief Executive Officer, John McCafferty was invited to attend the Nobel Prize Award Ceremony in recognition of his pivotal con...

Edison initiates coverage of ADL Bionatur Solutions forecasting an equity valuation of EUR 2.37 per share with an upside potential of 42%

DGAP-News: ADL Bionatur Solutions / Key word(s): Research Update 11.12.2018 / 10:40 The issuer is solely responsible for the content of this announcement. Edison initiates coverage of ADL Bionatur Solutions forecasting an equity valuation of EUR 2.37 per share with an upside potential of 42% - Potential upside of more than 42% compared to MAB closing price of EUR 1.66 on 10 December 20...

Dr. Reddy’s announces the launch of over-the-counter store brand equivalent of Prilosec OTC® (Omeprazole Delayed-Release) Tablets, 20 mg in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today the launch of Omeprazole Delayed-Release Tablets, 20 mg, an over-the-counter (OTC) store-brand equivalent of Prilosec® OTC (omeprazole delayed-release) Tablets, 20 mg, in the United States market a...

Monday 10th December 2018

Human antibody discovery could save lives from fungal killer

(University of Exeter) A new way to diagnose, treat and protect against stealth fungal infections that claim more than 1.5 million lives per year worldwide has been moved a step closer, according to research published in Nature Communications.

Maintaining the unlimited potential of stem cells

(Salk Institute) Scientists from the Salk Institute discovered a new protein complex that keeps the brakes on stem cells, allowing them to maintain their indefinite potential. The new complex, called GBAF and detailed in Nature Communications on Dec. 3, 2018, could provide a future target for regenerative medicine.

Quick Search


News Quicklinks